Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31

Else Marie Agger*, Ida Rosenkrands, Anja Weinreich Olsen, Graham Hatch, Ann Williams, Constantia Kritsch, Karen Lingnau, Alexander von Gabain, Claire Swetman Andersen, Karen Smith Korsholm, Peter Andersen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

116 Citations (Scopus)


In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the ability to augment the immune response and protective efficacy of the well-known mycobacterial vaccine antigen, Ag85B-ESAT-6. The IC31 adjuvant, consisting of a vehicle based on the cationic peptide KLKL5KLK and the immunostimulatory oligodeoxynucleotide ODN1a signalling through the TLR9 receptor, was found to promote highly efficient Th1 responses. The combination of Ag85B-ESAT-6 and IC31 exhibited significant levels of protection in the mouse aerosol challenge model of tuberculosis and a detailed analysis of the immune response generated revealed the induction of CD4 T cells giving rise to high levels of IFN-γ secretion. Furthermore, the combination of Ag85B-ESAT-6/IC31 was found to confer efficient protection in the guinea pig aerosol model of tuberculosis infection and is at present moving towards clinical testing.

Original languageEnglish
Pages (from-to)5452-5460
Number of pages9
Issue number26
Publication statusPublished - 29 Jun 2006

Bibliographical note

Funding Information:
This study was funded by the European Commision (contract no. LSHP-CT-2003-503367). We are grateful that the project was supported by the Austrian Federal Ministry for Economy and Labour as well as by the City of Vienna (WWFF).


  • Adjuvant
  • Tuberculosis
  • Vaccine


Dive into the research topics of 'Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31'. Together they form a unique fingerprint.

Cite this